{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:09:09Z","timestamp":1790996949244,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T00:00:00Z","timestamp":1663459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Intravitreally injected anti\u2010vascular endothelial growth factor (anti\u2010VEGF) agents are first\u2010line treatment for neovascular age\u2010related macular degeneration (nAMD). Phase 3 trials demonstrated non\u2010inferiority of anti\u2010VEGF therapy with brolucizumab compared with aflibercept in best corrected visual acuity (BCVA) gains, with superior anatomical outcomes after brolucizumab. The purpose of the review was to summarize real\u2010world efficacy and safety data on brolucizumab in patients with nAMD. The review protocol was registered with PROSPERO (ID: CRD42021290530). We conducted systematic searches in Embase, Medline and key ophthalmology congress websites (19 October 2021). Original reports of efficacy and\/or safety in patients receiving brolucizumab to treat nAMD in clinical practice were eligible. The descriptive summary includes reports describing at least 10 brolucizumab\u2010treated eyes. In total, 2907 brolucizumab\u2010treated eyes from 26 studies were included. Outcomes were available for treatment\u2010naive eyes (six studies), eyes switched to brolucizumab from other anti\u2010VEGFs (16 studies), and\/or treatment\u2010naive and switch eyes combined (eight studies). Follow\u2010up time points ranged from 4\u2009weeks to 1\u00a0year post\u2010brolucizumab initiation. For BCVA, significant improvements compared with brolucizumab initiation were reported in four of six studies in treatment\u2010naive eyes (mean BCVA improvement, range: +3.7 to +11.9 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) and in three of 12 studies in switch eyes (range: +9.0 to +15 ETDRS letters) (all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05); remaining studies reported no significant post\u2010brolucizumab BCVA changes. For central subfield thickness (CST), improvements post\u2010brolucizumab initiation were reported in all six studies in treatment\u2010naive eyes (mean CST improvement, range: \u2212113.4 to \u2212150.1\u00a0\u03bcm) and in eight of 11 studies in switch eyes (range: \u221226 to \u2212185.7\u00a0\u03bcm) (all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). The 14 studies reporting on intraretinal, subretinal and\/or total fluid observed improvements post\u2010brolucizumab initiation. The four studies comparing treatment intervals observed extension of the interval between injections after switching to brolucizumab from other anti\u2010VEGFs. Incidence of intraocular inflammation ranged from 0% to 19%. In conclusion, real\u2010world efficacy and safety data concur with brolucizumab pivotal trials. Additionally, reduction of disease activity in anti\u2010VEGF switch eyes was demonstrated by fluid reduction and\/or visual acuity gain, along with prolongation of the interval between injections.\n                  <\/jats:p>","DOI":"10.1111\/aos.15242","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:24:55Z","timestamp":1663547095000},"page":"123-139","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of brolucizumab in age\u2010related macular degeneration: A systematic review of real\u2010world studies"],"prefix":"10.1111","volume":"101","author":[{"given":"Caroline R.","family":"Baumal","sequence":"first","affiliation":[{"name":"New England Eye Center, Tufts Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-0199","authenticated-orcid":false,"given":"Torben Lykke","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"University of Copenhagen  Copenhagen Denmark"},{"name":"Department of Ophthalmology Zealand University Hospital Roskilde  Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Karcher","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita L.","family":"Freitas","sequence":"additional","affiliation":[{"name":"Novartis Farma \u2013 Produtos Farmac\u00eauticos, S.A.  Porto Salvo Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Becher","sequence":"additional","affiliation":[{"name":"Oxford PharmaGenesis  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Balez","sequence":"additional","affiliation":[{"name":"Novartis Pharma S.A.S.  Rueil Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"},{"name":"Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Singer","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center and Medical Center Ophthalmology  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[{"name":"University of Lyon and Croix\u2010Rousse University Hospital UCBL, INSA Lyon, CNRS, MATEIS, UMR5510, Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","unstructured":"Abdin A.D. Aljundi W. Weinstein I. Aljawhari K. Suffo S.&Seitz B.(2021)Intravitreal brolucizumab for treatment of refractory macular edema due to neovascular age\u2010related macular deneration (real life data) (European Society of Retina Specialists [EURETINA] congress presentation).","DOI":"10.3389\/fphar.2022.860784"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.0146"},{"key":"e_1_2_9_4_1","first-page":"451","article-title":"Real world efficacy and safety of brolucizumab in neovascular AMD: the REBEL study","volume":"62","author":"Aziz A.A.","year":"2021","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.4586"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.09.020"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132758"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184153"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-021-01474-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318672"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S328160"},{"key":"e_1_2_9_13_1","unstructured":"Cristian C. Mohla A. McKibbin M.&Mukherjee R.(2021)Early experience of brolucizumab use in a tertiary hospital setting for neovascular age\u2010related macular degeneration (nAMD) (European Society of Retina Specialists [EURETINA] congress presentation)."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","unstructured":"Eandi C.M.&Montesel A.(2021)Short\u2010term efficacy and safety outcomes of brolucizumab in the real\u2010life clinical practice (European Society of Retina Specialists [EURETINA] congress presentation).","DOI":"10.3389\/fphar.2021.720345"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.7085"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(82)90197-0"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.024"},{"key":"e_1_2_9_20_1","unstructured":"Fossataro F. Cozzi M. Maione G.&Pece A.(2021)Structural and vascular features in non\u2010responder neovascular age\u2010related macular degeneration after brolucizumab injection: an optical coherence tomography angiography study (European Society of Retina Specialists [EURETINA] congress presentation)."},{"key":"e_1_2_9_21_1","first-page":"1164","article-title":"Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy","volume":"9","author":"Fukuda Y.","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129361"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","unstructured":"Haensli C. Pfister I.B.&Garweg J.G.(2021a)Switching to brolucizumab in eyes incompletely responsive to ranibizumab or aflibercept: real\u2010life 6\u2010month outcomes (European Society of Retina Specialists [EURETINA] congress presentation).","DOI":"10.3390\/jcm10122666"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122666"},{"key":"e_1_2_9_25_1","first-page":"286","article-title":"A retrospective study on the use of brolucizumab for the treatment of NVAMD: a 1\u2010year private practice experience","volume":"62","author":"Hamou S.J.","year":"2021","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002670"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-021-01321-8"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","unstructured":"Hussain R.(2021)Real world experience of brolucizumab for persistent macular fluid in neovascular age\u2010related macular degeneration after prior anti\u2010VEGF treatments (American Society of Retina Specialists [ASRS] congress presentation).","DOI":"10.1177\/25158414211055964"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.04.028"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.4585"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05518-0"},{"key":"e_1_2_9_32_1","unstructured":"Kilani A. Vounotrypidis E. Arrow S. Reiterer V. Wertheimer C.&Wolf A.(2021)Intravitreal brolucizumab in poor\u2010responsive neovascular age\u2010related macular degeneration (European Society of Retina Specialists [EURETINA] congress presentation)."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01487-0"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05136-w"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86014-7"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2020-000669"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.720345"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02008-3"},{"key":"e_1_2_9_40_1","first-page":"431","article-title":"Real\u2010world analysis of brolucizumab in neovascular AMD","volume":"62","author":"Rave V.","year":"2021","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20210528-04"},{"key":"e_1_2_9_42_1","first-page":"668","article-title":"Biomarkers in early response to brolucizumab on pigment epithelium detachment associated with exudative age\u2010related macular degeneration","volume":"9","author":"Rispoli M.","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-1111-x"},{"key":"e_1_2_9_44_1","first-page":"432","article-title":"Cost efficacy and challenges of real\u2010world brolucizumab use for neovascular AMD","volume":"62","author":"Sharma K.","year":"2021","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.05.003"},{"key":"e_1_2_9_46_1","unstructured":"Sudhalkar A.A. Kodjikian L. Bilgic A. Mathis T.&Vasavada S.(2021)Brolucizumab in wet age related macular degeneration and polypoidal choroidal vasculopathy: real world evidence (European Society of Retina Specialists [EURETINA] congress presentation)."},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000513048"},{"key":"e_1_2_9_48_1","unstructured":"Walter S.D.&Saba N.J.(2021a)Efficacy and durability of brolucizumab in patients being transitioned from prior anti\u2010VEGF therapy (American Society of Retina Specialists [ASRS] congress presentation)."},{"key":"e_1_2_9_49_1","first-page":"456","article-title":"Real\u2010world efficacy and safety of brolucizumab","volume":"62","author":"Walter S.D.","year":"2021","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420975303"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.15242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.15242","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.15242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T15:15:30Z","timestamp":1692371730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.15242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,18]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/aos.15242"],"URL":"https:\/\/doi.org\/10.1111\/aos.15242","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,18]]},"assertion":[{"value":"2022-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}